The Pharma Data

NOVEMBER 5, 2020

and Aavis Pharmaceuticals Inc. The product will be distributed by Jubilant Cadista, a unit of Jubilant Pharma Ltd. “We are pleased to announce the commercial launch of Hydroxychloroquine Sulfate tablets in the U.S.through our marketing partner,” stated Ashok Barot , Chairman, Aavis Pharmaceuticals.

Marketing 40

Marketing Generic Pharmaceutical Contract Manufacturing Manufacturing 40

Pharmaceutical Technology

DECEMBER 22, 2022

This consists of any projects that have expanded the company’s footprint in the sector, including: contract wins; launching in new territories; launching new product lines; the acquisition and expansion of facilities and real estate; acquisition of new machinery or other assets; improved logistics; partnerships; and significant staff increases.

Insulin 130

Insulin Production Development Genetics 130

XTalks

JUNE 8, 2022

Biosimilars are generic versions of biologics medicines that already have regulatory approval (called the reference product) and have expired patents leading to a loss of exclusivity rights. As a result, the company is currently embroiled in legal disputes over claims of creating a market monopoly. percent.

Generic Pharmaceutical 69

Generic Pharmaceutical Branding Production Medicine 69

The Pharma Data

MAY 15, 2023

Before joining EMMI Group as CEO, he was a Member of the Executive Board and Head of the Marketing Department at Migros-Genossenschafts-Bund. He holds a Master degree in Marketing and Trade from the University of St. Nor can there be any guarantee that such products will be commercially successful in the future. Dr. Shamiram R.

Sales 40

Sales Production Doctors Doctor 40

Pharma in Brief

DECEMBER 3, 2023

The Regulations were meant to counterbalance the early-working exception by providing innovators with an enforcement tool to prevent patent infringement prior to generic or biosimilar market entry. These provisions were further amended in 2015 to clarify the level of product specificity required for combination drugs and formulations.

Regulation 52

Regulation Compliance Medicine Manufacturing 52

XTalks

AUGUST 2, 2023

We delve into the driving forces behind their successes and shed light on the groundbreaking research that has earned them a place among the elite in the pharmaceutical arena. is a global pharmaceutical company, working across both developed and emerging markets. The global revenue for Invega products was $4.14

Sales 98

Sales Manufacturing FDA Approval Life Science 98